Vanguard Portfolio Management
ALLO icon

Vanguard Portfolio Management’s Allogene Therapeutics ALLO Stock Holding History

Vanguard Portfolio Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.76M Buy
4,212,078
+2,517,966
+149% +$5.53M ﹤0.01% 2239
2026
Q1 		$4.13M Buy
+1,694,112
New +$3.4M ﹤0.01% 2383

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Portfolio Management's ALLO Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Allogene Therapeutics (ALLO) stake by 149% in Q2 2026, buying an estimated $5.53M and bringing the position to 4,212,078 shares worth $8.76M. The position accounts for ﹤0.01% of the portfolio, ranked #2239.

Vanguard Portfolio Management first reported a position in ALLO in Q1 2026 and has held it in 2 quarters since. 207 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Vanguard Portfolio Management held 4,212,078 shares of Allogene Therapeutics worth $8.76M as of Q2 2026.
  • Vanguard Portfolio Management bought 2,517,966 Allogene Therapeutics shares in Q2 2026, an estimated $5.53M.
  • Allogene Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2239 holding.
  • Vanguard Portfolio Management first reported a position in Allogene Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 207 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.